▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3675 by analyst upside · 2026-09-27
REGN
Regeneron Pharmaceuticals, Inc.
Healthcare · Market Cap $81B · P/E 19.5x
ANALYST PRICE TARGET
+8.0%
implied upside to consensus target
Current Price $788.04
Consensus Target $850.88
Bull Target $1030.0
Bear Target $730.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
13
Hold
9
Sell
0
52-Week Low $541.0
52-Week High $859.34
YTD Return +1.9%
FUNDAMENTALS
Market Cap $81B
P/E Ratio (TTM) 19.5x
Forward P/E 12.9x
EPS (TTM) $40.43
PEG Ratio 1.30
Dividend Yield 0.48%
Revenue (TTM) $15.5B
Profit Margin 27.9%
52-WEEK RANGE
52-Week Low $541.0
52-Week High $859.34
Current Price $788.04
Bear Target $730.0
Bull Target $1030.0
● Now $788.04 ● Target $850.88
TRADING DATA
Avg Volume 750K
YTD Return +1.9%
Analyst Count 26
Consensus Buy
Upside to Target +8.0%
Last Updated 2026-09-27

ANALYST SUMMARY

Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at $788.04 with a Wall Street consensus price target of $850.88, implying potential upside of 8.0% over the next 12 months. 26 analysts currently cover REGN, with a consensus rating of Buy - 65% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1030.0, while the most cautious has a target of $730.0.

REGN operates in the Healthcare sector with a market capitalisation of $81B. The stock is up 1.9% year-to-date and is currently trading near the upper end of its 52-week range of $541.0 – $859.34.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ELV +14.0%
Elevance Health, Inc.
$86B · P/E 17.5x · Buy
HCA +4.3%
HCA Healthcare, Inc.
$94B · P/E 14.6x · Buy
MCK +13.0%
McKesson Corporation
$101B · P/E 23.3x · Buy
CI +25.7%
The Cigna Group
$72B · P/E 11.2x · Buy
SYK +35.5%
Stryker Corporation
$104B · P/E 28.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for REGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HSBC - Reiterated
Buy → Buy 2026-09-10 Building track record
Leerink Partners - Reiterated
Market Perform → Market Perform 2026-08-17 29% win rate (7 calls)
Citigroup - Reiterated
Neutral → Neutral 2026-08-03 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-08-03 62% win rate (8 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-07-31 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-07-31 Building track record
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-07-31 40% win rate (10 calls)
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-07-31 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →